Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma.
The cost-effectiveness of high-dose chemotherapy in multiple myeloma was considered as part of a UK National Health Service Executive regional evidence-based appraisal process. The use of high-dose chemotherapy supported by autologous stem cell transplantation in patients under 65 years of age was shown to provide a marginal benefit of 0.7 life-years over conventional chemotherapy. This corresponded to an incremental cost 'per life-year gained' figure of approximately pound15 000, based upon initial treatment costs and trial-period data only. The use of high-dose chemotherapy in the first-line treatment of advanced multiple myeloma improves event-free and overall survival and appears to be a cost-effective treatment option.
Sampson
F C
FC
School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK. f.c.sampson@sheffield.ac.uk
Beard
S M
SM
Scott
F
F
Vandenberghe
E
E
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics*; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D016527:Drug Costs; D019317:Evidence-Based Medicine; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000191:economics / Q000601:surgery; D011788:Quality of Life; D013222:State Medicine / Q000191:economics; D006113:United Kingdom
D000970:Antineoplastic Agents